RANCHO CORDOVA, Calif.


,


Sept. 7, 2022


/PRNewswire/ — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that

Chris Xu

, Ph.D., Chief Executive Officer, will present a company overview at the H.C. Wainwright 24

^th

Annual Global Investment Conference, taking place

September 12-14, 2022

.  Details of Dr. Xu’s in-person presentation are as follows:

Date

:

Wednesday, September 14, 2022



Time

:

12:00pm Eastern Time

Dr. Xu will also host in-person and virtual one-on-one meetings during the event. Institutional investors who are registered for the conference can log into

www.hcwevents.com

to request a meeting with the company

A live webcast of the presentation will be available on the ThermoGenesis website at:

https://ThermoGenesis.com/investors/news-and-events/events-webcasts

.

An archived replay will be available for a period of 90 days after the conference.

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit:

www.thermogenesis.com

.

Company Contact:



Wendy Samford


916-858-5191


[email protected]

Investor Contact:


Paula Schwartz, Rx Communications

917-322-2216


[email protected]

View original content:

https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301619020.html

SOURCE ThermoGenesis Holdings, Inc.